Cancer, Hematologic Neoplasms, Solid Tumor
Conditions
Keywords
Cancer, Methylation, cfDNA, Solid Tumor, Hematologic Neoplasms
Brief summary
Nucleix EpiCheck® tests analyzes the methylation pattern in a panel of DNA methylation biomarkers and determines whether this pattern is consistent with cancer under test or with non-cancer tissue. This study is being performed as part of the development process of the Pan Cancer EpiCheck test which includes the identification of different methylation profiles in various cancer types and healthy controls.
Detailed description
The aim of this study is to characterize methylation patterns that will distinguish cancer from normal samples and will be able to recognize the origin of the cancer by collecting cfDNA (circulating free DNA) from blood samples collected from patients with a new diagnosis of cancer and from healthy volunteers who do not have diagnosis or history of cancer. Identifying those methylation patterns may assist in the development of blood test that will be able to detect the presence and the origin of wide range of human cancers
Interventions
PROCEDUREBlood collection
Peripheral blood collection via routine venipuncture
Sponsors
Nucleix Ltd.
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
22 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
- Cases: 1. Age ≥ 22 years 2. Subjects who are willing and able to provide written informed consent. 3. Subjects with confirmed diagnosis of cancer (primary or recurrent) at all stages, however did not yet undergo any surgery, chemotherapy, radiation or any other treatment for this cancerous lesion (including, but not limited to systemic therapies). Recent cancer staging should be within 60 days prior to baseline visit.
Exclusion criteria
- Cases: 1. Known prior diagnosis of cancer except of: 1. Fully resected non-melanoma skin cancer 2. History of the original cancer in cases of recurrent disease. 2. Current co-diagnosis of another type of cancer. 3. Currently receiving, or ever received, any of the following therapies to treat their current cancer: surgical management of the cancer beyond that required to establish the cancer diagnosis; local, regional or systemic chemotherapy including chemoembolization; targeted therapy, immunotherapy including cancer vaccines; hormone therapy; or radiation therapy 4. Pregnancy (by self-report) 5. Current febrile illness 6. Acute exacerbation or flare of an inflammatory condition requiring escalation in medical therapy within 14 days prior to blood draw. 7. Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant Inclusion Criteria - Controls: 1. Age 45 to 80 years 2. Subjects who are willing and able to provide written informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To collect blood and urine samples and clinical data in order to characterize methylation patterns that will discriminate cancer and normal (non-cancer) samples and the origin of cancer | 72 Months | To collect blood and urine samples and clinical data in order to characterize methylation patterns that will discriminate cancer and normal (non-cancer) samples and the origin of cancer |
| To develop a molecular blood test that will be able to detect wide range of human cancers based on change in methylation patterns between cancer and normal samples | 72 Months | To develop a molecular blood test that will be able to detect wide range of human cancers based on change in methylation patterns between cancer and normal samples |
Countries
Israel, United States
Outcome results
None listed